Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target
Authors
Keywords
-
Journal
Molecular Oncology
Volume 8, Issue 8, Pages 1508-1520
Publisher
Wiley
Online
2014-06-13
DOI
10.1016/j.molonc.2014.06.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).
- (2017) Richard D. Carvajal et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-derived xenografts recapitulate molecular features of human uveal melanomas
- (2013) Cécile Laurent et al. Molecular Oncology
- Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3
- (2013) Marcel Martin et al. NATURE GENETICS
- Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
- (2013) J William Harbour et al. NATURE GENETICS
- SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma
- (2013) S. J. Furney et al. Cancer Discovery
- Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner
- (2012) J. S. Khalili et al. CLINICAL CANCER RESEARCH
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Genetic and molecular characterization of uveal melanoma cell lines
- (2012) K. G. Griewank et al. Pigment Cell & Melanoma Research
- The genetics of uveal melanoma: an emerging framework for targeted therapy
- (2012) J. William Harbour Pigment Cell & Melanoma Research
- Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype
- (2012) Alan L. Ho et al. PLoS One
- RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
- (2012) Beat Nyfeler et al. PLoS One
- Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe
- (2011) S. Mallone et al. EUROPEAN JOURNAL OF CANCER
- PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
- (2011) B Weigelt et al. ONCOGENE
- Uveal Melanoma: Trends in Incidence, Treatment, and Survival
- (2011) Arun D. Singh et al. OPHTHALMOLOGY
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors
- (2010) F. Nemati et al. CLINICAL CANCER RESEARCH
- Local Tumor Control, Visual Acuity, and Survival After Hypofractionated Stereotactic Photon Radiotherapy of Choroidal Melanoma in 212 Patients Treated Between 1997 and 2007
- (2010) Roman Dunavoelgyi et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma
- (2010) Helena Pópulo et al. MELANOMA RESEARCH
- Mutations inGNA11in Uveal Melanoma
- (2010) Catherine D. Van Raamsdonk et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics
- (2010) H. Pópulo et al. Pigment Cell & Melanoma Research
- Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
- (2010) J. W. Harbour et al. SCIENCE
- Genome-wide copy number alterations detection in fresh frozen and matched FFPE samples using SNP 6.0 arrays
- (2008) Marianne Tuefferd et al. GENES CHROMOSOMES & CANCER
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
- (2008) Catherine D. Van Raamsdonk et al. NATURE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started